Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis

Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells

(2015) T Y Prudnikova et al.   ONCOGENE

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

(2015) Alexei S. Karpov et al.   ACS Medicinal Chemistry Letters

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety

(2015) Chudi O. Ndubaku et al.   ACS Medicinal Chemistry Letters

Group I Paks as therapeutic targets in NF2-deficient meningioma

(2015) Hoi-Yee Chow et al.   Oncotarget

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity

(2015) Adrienne L. Watson et al.   Oncotarget

Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1-Mutant Cancers

(2014) C. F. Malone et al.   Cancer Discovery

Pak1 Kinase Links ErbB2 to  -Catenin in Transformation of Breast Epithelial Cells

(2013) L. E. Arias-Romero et al.   CANCER RESEARCH

CXCR4/CXCL12 Mediate Autocrine Cell- Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath Tumors

(2013) Wei Mo et al.   CELL

The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis

(2013) A. Luscan et al.   CLINICAL CANCER RESEARCH

Mesenchymal to epithelial transition in sarcomas

(2013) Jilong Yang et al.   EUROPEAN JOURNAL OF CANCER

Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance

(2013) Adrienne L. Watson et al.   Cancer Discovery

Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors

(2012) M. Endo et al.   CLINICAL CANCER RESEARCH

Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis

(2012) Meena Upadhyaya et al.   HUMAN MUTATION

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

(2012) Walter J. Jessen et al.   JOURNAL OF CLINICAL INVESTIGATION

Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1

(2012) M. Kolberg et al.   NEURO-ONCOLOGY

Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms

(2011) Steven L. Carroll   ACTA NEUROPATHOLOGICA

P-21 activated kinase 1 knockdown inhibits β-catenin signalling and blocks colorectal cancer growth

(2011) Hong He et al.   CANCER LETTERS

Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

(2011) K. E. Torres et al.   CLINICAL CANCER RESEARCH

PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling

(2011) Y Shrestha et al.   ONCOGENE

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

(2010) E. B. Haura et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

p21-Activated Kinases Are Required for Transformation in a Cell-Based Model of Neurofibromatosis Type 2

(2010) Hoi Yee Chow et al.   PLoS One

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

(2009) Bryan T. MacDonald et al.   DEVELOPMENTAL CELL

Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways

(2009) Daniela Katz et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors

(2009) Brigitte C. Widemann   Current Oncology Reports

An Isoform-Selective, Small-Molecule Inhibitor Targets the Autoregulatory Mechanism of p21-Activated Kinase

(2008) Sean W. Deacon et al.   CHEMISTRY & BIOLOGY

E-cadherin expression in postnatal Schwann cells is regulated by the cAMP-dependent protein kinase a pathway

(2008) Audrita T. Crawford et al.   GLIA

How does the Schwann cell lineage form tumors in NF1?

(2008) Steven L. Carroll et al.   GLIA

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors

(2008) G. Johansson et al.   MOLECULAR CANCER THERAPEUTICS

UnPAKing the class differences among p21-activated kinases

(2008) Jeyanthy Eswaran et al.   TRENDS IN BIOCHEMICAL SCIENCES